Patents by Inventor Peter Kotanko

Peter Kotanko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120253022
    Abstract: The invention is directed to a method of removing a deleterious substance bound to a protein in blood of a patient by introducing a displacer substance into the blood under conditions in which the displacer substance replaces deleterious substance bound to the protein, thereby resulting in additional unbound deleterious substance in the blood, and removing unbound deleterious substance from the blood by extracorporeal renal replacement treatment.
    Type: Application
    Filed: June 12, 2012
    Publication date: October 4, 2012
    Applicant: Fresenius Medical Care Holdings, Inc.
    Inventors: Peter Kotanko, Nathan W. Levin
  • Patent number: 8206591
    Abstract: The invention is directed to a method of removing a deleterious substance bound to a protein in blood of a patient by introducing a displacer substance into the blood under conditions in which the displacer substance replaces deleterious substance bound to the protein, thereby resulting in additional unbound deleterious substance in the blood, and removing unbound deleterious substance from the blood by extracorporeal renal replacement treatment.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: June 26, 2012
    Assignee: Fresenius Medical Care Holdings, Inc.
    Inventors: Peter Kotanko, Nathan W. Levin
  • Publication number: 20110237996
    Abstract: A method of performing regional citrate anticoagulant dialysis of a patient's blood includes flowing blood from and back to the patient through an extracorporeal circuit including a dialyzer having semi-permeable dialysis membranes and a dialysate chamber surrounding the membranes. The method further includes flowing a dialysate containing calcium and citrate through the dialysate chamber of the dialyzer and introducing citrate into the patient's blood upstream of the dialyzer, whereby the patient's blood is dialyzed. The method can further include predicting the concentration of systemic ionized calcium in the blood of the patient at any point in the dialysis treatment or post-dialysis, such as by a mathematical model. The method can further include statistically correcting the preliminary predicted post-dialysis concentration of systemic ionized calcium in the patient's blood to provide a final predicted post-dialysis systemic ionized calcium concentration.
    Type: Application
    Filed: June 17, 2010
    Publication date: September 29, 2011
    Applicant: Fresenius Medical Care Holdings, Inc.
    Inventors: Peter Kotanko, Stephan Thijssen, Nathan W. Levin
  • Publication number: 20110137136
    Abstract: The invention is directed to a method of identifying a patient undergoing periodic hemodialysis treatments at increased risk for death that includes determining at least one of the patient's clinical or biochemical parameters, including systolic blood pressure, serum albumin concentration level, body weight, body temperature, serum bicarbonate concentration level, serum potassium concentration level, serum calcium concentration level, hemoglobin concentration level, serum phosphorus concentration level, neutrophil to lymphocyte ratio, equilibrated normalized protein catabolic rate (enPCR), equilibrated fractional clearance of total body water by dialysis and residual kidney function (eKdrt/V), EPO resistance index, transferrin saturation index, serum ferritin concentration level, serum creatinine concentration level, platelet count, Aspartat-Aminotransferase level, and Alanin-Aminotransferase level at periodic hemodialysis treatments, and identifying a patient as having an increased risk for death if the pati
    Type: Application
    Filed: December 2, 2010
    Publication date: June 9, 2011
    Applicant: Fresenius Medical Care Holdings, Inc.
    Inventors: Peter Kotanko, Stephan Thijssen, Len Usvyat, Nathan W. Levin
  • Publication number: 20110079558
    Abstract: A method of controlling diffusive sodium transport from the dialysate solution to the blood of a patient undergoing hemodialysis treatment or from the blood to the dialysate solution includes calculating SNa+average, an average of the patient's historic serum sodium concentrations, and estimating SNa+estimated, the patient's pre-dialysis serum sodium concentration, based on the average of the patient's measured historic pre-dialysis serum sodium concentrations, SNa+measured. The method enables adjusting DNa+, the sodium concentration of the dialysate solution, based on the average of the patient's historic serum sodium concentrations, SNa+average, if needed, and performing the dialysis treatment of the patient using a dialysate solution containing a sodium concentration DNa+.
    Type: Application
    Filed: October 1, 2010
    Publication date: April 7, 2011
    Applicant: Fresenius Medical Care Holdings, Inc.
    Inventors: Jochen G. Raimann, Erik Lars Penne, Stephan Thijssen, Peter Kotanko, Nathan W. Levin
  • Publication number: 20100096330
    Abstract: The invention is directed to a method of determining a dosage of phosphorus binder for a patient undergoing dialysis treatment to achieve a pre-dialysis serum phosphorus concentration within a desired concentration range while achieving a desired net accumulation of calcium. The method includes determining the dosage of phosphorus binder that will achieve pre-dialysis serum phosphorus concentration of the patient that is within the desired concentration range while accounting for the change in the amount of phosphorus removed by the dialysis treatment when the pre-dialysis serum phosphorus concentration of the patient is within the desired concentration range, determining a dialysate calcium concentration that will result in the desired net accumulation of calcium over a complete dialysis cycle, and dialyzing the patient with a dialysate containing a calcium concentration based upon that determination.
    Type: Application
    Filed: October 16, 2009
    Publication date: April 22, 2010
    Applicant: Fresenius Medical Care Holdings, Inc.
    Inventors: Frank A. Gotch, Benjamin J. Lipps, Peter Kotanko, Nathan W. Levin, Amanda K. Stennett, Norman J. Ofsthun
  • Publication number: 20100099958
    Abstract: The invention is directed to a method of identifying a patient undergoing periodic hemodialysis treatments at increased risk for death that includes determining at least one of the patient's systolic blood pressure, serum albumin level, body weight, and body temperature at periodic hemodialysis treatments, and identifying a patient as having an increased risk for death if the patient has a substantial change in the rate of decline of at least one of the patient's systolic blood pressure, serum albumin level, body weight, and body temperature. The invention is also directed to a method of identifying an increased mortality risk factor for a patient undergoing periodic hemodialysis treatment.
    Type: Application
    Filed: October 15, 2009
    Publication date: April 22, 2010
    Applicant: Fresenius Medical Care Holdings Inc.
    Inventors: Peter Kotanko, Stephan Thijssen, Len Usvyat, Nathan W. Levin
  • Publication number: 20100096329
    Abstract: The invention is directed to a method of removing a deleterious substance bound to a protein in blood of a patient by introducing a displacer substance into the blood under conditions in which the displacer substance replaces deleterious substance bound to the protein, thereby resulting in additional unbound deleterious substance in the blood, and removing unbound deleterious substance from the blood by extracorporeal renal replacement treatment.
    Type: Application
    Filed: October 15, 2009
    Publication date: April 22, 2010
    Applicant: Fresenius Medical Care Holdings, Inc.
    Inventors: Peter Kotanko, Nathan W. Levin